Treatment and diagnosis of ocular disease

1. A method of treating a disease characterized by ocular inflammation, the method comprising administering a pharmaceutical composition to a subject in need of such treatment in an amount effective to reduce said inflammation, wherein the pharmaceutical composition comprises a leukotoxin comprising SEQ ID NO: 1 and an ophthalmologically acceptable carrier, and wherein the disease is an ocular inflammatory disease, wherein the pharmaceutical composition is administered topically to the ocular region.

2. A method of reducing ocular inflammation in an ocular region within a subject in need thereof, characterized by increased levels of activated white blood cells in a subject in need thereof, the method comprising administering to the subject an amount of a pharmaceutical composition in amount effective to reduce said ocular inflammation, wherein the pharmaceutical composition comprises a leukotoxin comprising SEQ ID NO: 1 and an ophthalmologically acceptable carrier suitable for ocular administration, wherein the pharmaceutical composition is administered topically to the ocular region.

3. The method of claim 1 , wherein the leukotoxin is prepared from Aggregatibacter actinomycetemcomitans.

4. The method of claim 1 , wherein the ocular inflammatory disease is selected from the group consisting of keratoconjunctivitis sicca, diabetic retinopathy, diabetic macula edema, dry eye, scleritis, birdshot retinochoriodopathy, ocular cicatricial pemphigoidm, keratitis, sympathetic ophthalmia, vogt-koyanagi harada, fuchs' heterochromic iridocyclitis, uveitis, pars planitis, episcleritis, optic neuritis, orbital pseudotumor, retinal vasculitis, ocular allergy, and chronic conjunctivitis.

5. The method of claim 1 , wherein the amount administered to said subject is effective to reduce local cytokine levels in the ocular region.

6. The method of claim 1 , wherein one or more cytokines are selected from the group consisting of IL-4, IL-5, IL-9, IL17F and IL-23α.

7. The method of claim 1 , wherein the pharmaceutical composition is formulated for and administered by using an eye drop dispenser.

8. The method of claim 2 , wherein the activated white blood cells express a greater level of LFA-1 compared to white blood cells from a normal healthy subject.

9. The method of claim 2 , wherein the inflammation is caused by a disease or condition selected from the group consisting of an infection, autoimmune disease, allergen, ocular trauma, and ocular allograft rejection.

10. The method of claim 9 , wherein the infection may be caused by a virus, bacteria, or a fungus.

11. The method of claim 1 , wherein the ophthalmologically acceptable carrier is selected from the group consisting of an eye gel, eye cream, suspension-type eye drops, eye wash, ointment, gel, liposomal dispersion, colloidal microparticle suspension, implant and a contact lens.